Member Info for violindog

Drac, you are correct re the sales..as for Redmile...whatever raises the SP...nothing else is achieving this, even after the numerous conferences.

Almost a year since any Moditope update....we must be due something to help support this miserable SP . At this rate of progress we will run out of capital before trial results and unless Redmile supports Scancell...a fire sale is the only way out.

Indeed...the same "core" of folk must attend these conferences. They must yawn through Scancell’s presentations by now.

27/43...so another 16 pts to be recruited by the end of June .

Empty...I get 13pts in the first stage of the trial with 11 responders....then the article says ...

"The SCOPE trial is in its second stage, with 27 of 43 total patients now enrolled. Recruitment is expected to conclude in the second quarter of 2024, and additional data are expected in the fourth quarter of 2024."

Yes the article says "Twenty-four patients have now received SCIB1 as part of the study." Perhaps the other 3 of the 27 have been "recruited" but not yet dosed ???.

Yes, an impressive list and alot to hope for ...guess our fate depends on the timescale of delivery and the subsequent SP reaction.

Ruck, you make valid points....certainly no secret that I would jump at 50p !!

Scancell’s Web page still has errors.....LDs options @ 4.5p with the wrong expiry date. The option date was extended .

EE, your 13:11 post is spot on !! I think it summaries so many points and concerns.

Hopefully within the time frame of 6-12 months shareholders will reap some of the rewards for what has been an exceptionally long investment for many. So many positives , we just need our strengthened managment team to deliver on the back of hopefully excellent results. I don't think we will ever follow the likes of BioNtec on the growth path , certainly failed so far, but the continued strong dollar, and the miserable market environment on Aim... combined with promising trial results... may prompt a takeover bid .

Burble...perhaps it is a question of "deep pockets" from BioNtec and Moderna "paying" for publicity !

EE, "The exit route here is a corporate deal, at some point in the next year or so, on the back of trial results and proof of platforms….."

Indeed...or as bugs bunny would say ...that's it folks !!

Let's get those deals done ✔️

TF, pleased for you it's a wee bit cooler 😎. Re the RNS....I can hardly lecture folks on being patient... but I guess it will come. At least we are at the prestigious conference and LD will be promoting Scancell . Perhaps Scancell are able to have "off the record discussions " .

I'm fully loaded with shares .. but a great opportunity at these prices . GLA !!

Goodmorning TF....up early in anticipation... hope the weather is cooler for you .

KonarA, your 16:49 post is excellent indeed. The ethical stance is a very logical argument....the conference would be an excellent forum for Scancell to present stunning results. ....🤞...as ever.

Thanks DeAar for posting the link 👍

Rat, yes, it reads very very well.... 85% ORR and no serious side affects !! Excellent !! I'm sure Lindy can say an awfull lot more "off the record" at the conference 😉

Hi TF , thanks for your post. Yes , frustration does get the better of me sometimes. It's just that I can see so many positive aspects to Scancell...I can't understand why it wouldn't get snapped up by a major.

KonarA , I guess I have to divorce the market cap from potential deals. I accept others on this bb know far more than I do.

TF, enjoy your trip up north and remember to drink plenty of water in the heat. I would love some sun and heat....fed up of the UK weather..wet..wet .

So guys, promise to hold my frustration before posting .

Shame Genmab didn't like what Scancell has available to offer....unless a price couldn't be agreed. One day ! Interesting that they are a private company, could Genmab justify the price tag to their shareholders if they were trading for 10p and a market cap of 95million ?? No wonder companies like Redex delist .

SEATTLE, Washington; April 3, 2024 – Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).

Six months is a long time to release an RNS..... add to this updating the Directors' Share Options section and the name of their auditors.....sloppy housekeeping indeed.

Shame folk are obviously keen to sell into any tiny rise ...oh well..